C. Rémuzat

1.2k total citations
62 papers, 760 citations indexed

About

C. Rémuzat is a scholar working on Economics and Econometrics, Pediatrics, Perinatology and Child Health and Physiology. According to data from OpenAlex, C. Rémuzat has authored 62 papers receiving a total of 760 indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Economics and Econometrics, 9 papers in Pediatrics, Perinatology and Child Health and 9 papers in Physiology. Recurrent topics in C. Rémuzat's work include Pharmaceutical Economics and Policy (46 papers), Health Systems, Economic Evaluations, Quality of Life (42 papers) and Biomedical Ethics and Regulation (9 papers). C. Rémuzat is often cited by papers focused on Pharmaceutical Economics and Policy (46 papers), Health Systems, Economic Evaluations, Quality of Life (42 papers) and Biomedical Ethics and Regulation (9 papers). C. Rémuzat collaborates with scholars based in France, United States and Italy. C. Rémuzat's co-authors include Mondher Toumi, Pascal Auquier, Ehab Y. Hanna, A. Millier, Samuel Aballéa, Matthias C. Angermeyer, Bruno Falissard, J Dorey, A. Kornfeld and C. Chouaïd and has published in prestigious journals such as SHILAP Revista de lepidopterología, BMC Psychiatry and Value in Health.

In The Last Decade

C. Rémuzat

60 papers receiving 724 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Rémuzat France 14 346 166 124 102 96 62 760
Phuong Bich Tran United States 15 83 0.2× 100 0.6× 217 1.8× 99 1.0× 65 0.7× 42 1.1k
Heather Zierhut United States 20 99 0.3× 29 0.2× 402 3.2× 54 0.5× 306 3.2× 74 1.4k
Katie L. Lewis United States 21 83 0.2× 23 0.1× 99 0.8× 67 0.7× 116 1.2× 49 1.0k
Adam Lowy Switzerland 16 80 0.2× 87 0.5× 193 1.6× 48 0.5× 30 0.3× 20 874
Satish Valluri United States 13 53 0.2× 105 0.6× 94 0.8× 12 0.1× 107 1.1× 37 644
Amber L. Mueller United States 9 55 0.2× 55 0.3× 293 2.4× 106 1.0× 12 0.1× 16 988
Pritibha Singh United States 13 116 0.3× 106 0.6× 33 0.3× 47 0.5× 20 0.2× 30 567
Carla van El Netherlands 19 117 0.3× 16 0.1× 312 2.5× 212 2.1× 338 3.5× 58 1.7k
Lindsay Boyce United States 8 20 0.1× 119 0.7× 108 0.9× 52 0.5× 62 0.6× 16 1.1k

Countries citing papers authored by C. Rémuzat

Since Specialization
Citations

This map shows the geographic impact of C. Rémuzat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Rémuzat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Rémuzat more than expected).

Fields of papers citing papers by C. Rémuzat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Rémuzat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Rémuzat. The network helps show where C. Rémuzat may publish in the future.

Co-authorship network of co-authors of C. Rémuzat

This figure shows the co-authorship network connecting the top 25 collaborators of C. Rémuzat. A scholar is included among the top collaborators of C. Rémuzat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Rémuzat. C. Rémuzat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rémuzat, C., et al.. (2019). PNS235 ASSESSMENT OF DIGITAL HEALTH TECHNOLOGIES - COMPARISON OF EVIDENCE FRAMEWORKS OF NICE AND HAS. Value in Health. 22. S801–S801. 2 indexed citations
2.
Rémuzat, C., C. François, & Mondher Toumi. (2018). PHP302 - HOW AFFORDABILITY IS CONSIDERED FOR PRICING POLICIES?. Value in Health. 21. S202–S202.
3.
Rémuzat, C., et al.. (2017). Could Healthcoin Be A Revolution In Healthcare?. Value in Health. 20(9). A672–A672. 2 indexed citations
4.
Rémuzat, C., et al.. (2016). Early Market Access for Pharmaceuticals in EU: What is the Impact of Ema’s Accelerated Assessment Procedure?. Value in Health. 19(7). A469–A469. 2 indexed citations
5.
Rémuzat, C. & Mondher Toumi. (2016). Value Added Medicines: The Need To Establish One Common Terminology For Repurposed Medicines. Value in Health. 19(7). A463–A464. 2 indexed citations
6.
Rémuzat, C. & Mondher Toumi. (2016). Health Care System Inefficiencies Related to Medicines: Any Potential Room for Improvement?. Value in Health. 19(7). A497–A497. 1 indexed citations
7.
Rémuzat, C., et al.. (2016). Risk of Discontinuation of Advanced Therapy Medicinal Products Clinical Trials. Value in Health. 19(7). A821–A822. 4 indexed citations
8.
9.
Rémuzat, C., C. Chouaïd, Pascal Auquier, et al.. (2016). Expected Impact of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (Esmo-Mcsb) on Health Technology Assessment. Value in Health. 19(7). A358–A359. 3 indexed citations
10.
Toumi, Mondher, et al.. (2015). Adaptive Pathways May Expand The Gap Between Regulators And Payers. Value in Health. 18(7). A574–A574. 1 indexed citations
11.
Rémuzat, C., et al.. (2015). Biosimilar Substitution Policies: An Overview. Value in Health. 18(7). A525–A525. 2 indexed citations
12.
13.
Rémuzat, C., et al.. (2015). Potential Societal Value of Biosimilars Adoption: The Example of UK. Value in Health. 18(7). A562–A562. 2 indexed citations
14.
Hanna, Ehab Y., et al.. (2015). Market Access of Atmps: Overview and Expected Challenges. Value in Health. 18(7). A518–A519. 7 indexed citations
15.
Angermeyer, Matthias C., et al.. (2014). Continuum beliefs and attitudes towards people with mental illness: Results from a national survey in France. International Journal of Social Psychiatry. 61(3). 297–303. 35 indexed citations
16.
Rémuzat, C., et al.. (2014). Price Dynamics Of External Reference Pricing-Based Systems In Europe. Value in Health. 17(3). A11–A11. 3 indexed citations
17.
Rémuzat, C., et al.. (2014). Comparative Analysis of Hta Decisions, Price and Reimbursement Level of Orphan Drugs In France and Italy. Value in Health. 17(7). A539–A540. 1 indexed citations
18.
Rémuzat, C., et al.. (2014). Boosting Biosimilars Uptake in European Countries. Value in Health. 17(7). A408–A409. 5 indexed citations
19.
Samp, Jennifer C., et al.. (2013). Routine clinical assessment of cognitive functioning in schizophrenia, major depressive disorder, and bipolar disorder. European Neuropsychopharmacology. 24(1). 133–141. 20 indexed citations
20.
Rémuzat, C., et al.. (2013). Pharmaceutical Expenditure Forecast Model To Support Health Policy Decision Making. Value in Health. 16(3). A255–A255. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Phuong Bich Tran Breakdown of academic impact, for papers by Heather Zierhut Breakdown of academic impact, for papers by Katie L. Lewis Breakdown of academic impact, for papers by Adam Lowy Breakdown of academic impact, for papers by Satish Valluri Breakdown of academic impact, for papers by Amber L. Mueller Breakdown of academic impact, for papers by Pritibha Singh Breakdown of academic impact, for papers by Carla van El Breakdown of academic impact, for papers by Lindsay Boyce
Rankless by CCL
2026